antibody for Phase 1 clinical supply. A cell line producing the
humanized anti-Trop-2 antibody was successfully transferred to
- Preparing for a pre-IND meeting with the FDA.
- ARIUS intends to have clinical trials' materials prepared in the
fourth quarter of 2008 and then a Phase I IND application is expected
to be filed and human clinical trials commenced.
CD59 Complement Inhibitor Program
- Presented a CD59-focused poster at AACR Annual Meeting.
- Generated a cell line producing humanized CD59 antibody that
successfully retained binding characteristics and potent in vivo
- Preparing to perform preclinical toxicology studies planned for 2008
in preparation for a Pre-IND meeting with the FDA and filing a
Phase I IND application.
CD9 Cancer Stem Cell Program
- Presented a CD9-focused poster at AACR Annual Meeting.
- Presented positive findings demonstrating the ability of the lead
anti-CD9 antibody to kill cancer stem cells in an in vivo model using
cells from human leukemia patients at the American Association of
Cancer Research Special Conference on Cancer Stem Cells in the first
quarter of 2008.
CD63 Antibody Program
- Licensed to Genentech, Inc. in March 2006, the CD63 program continues
to advance in preclinical studies in a variety of cancer indications
as part of a program to move the lead antibody towards the clinic.
- Discovered and delivered novel antibodies to Takeda. Under the terms
of the research collaboration agreement, ARIUS has successfully met
its obligations to date and has received all scheduled research
payments from Takeda.
Additional Product Updates
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved